Emergent Biosolutions (NYSE:EBS)‘s stock had its “buy” rating restated by investment analysts at Chardan Capital in a research note issued to investors on Thursday, AnalystRatings.com reports. They currently have a $71.00 price target on the biopharmaceutical company’s stock. Chardan Capital’s price target would suggest a potential upside of 31.38% from the stock’s current price.
EBS has been the subject of a number of other research reports. Laidlaw set a $72.00 price objective on shares of Emergent Biosolutions and gave the company a “buy” rating in a report on Wednesday, September 4th. Cowen reiterated a “hold” rating and issued a $67.00 price objective on shares of Emergent Biosolutions in a report on Thursday. Wells Fargo & Co upgraded shares of Emergent Biosolutions from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $61.00 to $64.00 in a report on Wednesday, September 4th. ValuEngine upgraded shares of Emergent Biosolutions from a “hold” rating to a “buy” rating in a report on Wednesday, September 4th. Finally, Guggenheim started coverage on shares of Emergent Biosolutions in a research note on Thursday, September 12th. They issued a “buy” rating and a $65.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Emergent Biosolutions currently has a consensus rating of “Buy” and a consensus target price of $69.00.
EBS stock traded down $0.96 during mid-day trading on Thursday, reaching $54.04. The company’s stock had a trading volume of 350,011 shares, compared to its average volume of 451,394. The stock has a market cap of $3.00 billion, a PE ratio of 23.19, a P/E/G ratio of 0.96 and a beta of 1.55. The company has a current ratio of 2.30, a quick ratio of 1.53 and a debt-to-equity ratio of 0.84. Emergent Biosolutions has a fifty-two week low of $39.11 and a fifty-two week high of $73.89. The company’s 50 day moving average is $54.01 and its two-hundred day moving average is $48.08.
Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $1.21 EPS for the quarter, beating the Zacks’ consensus estimate of $0.63 by $0.58. The company had revenue of $311.80 million during the quarter, compared to the consensus estimate of $289.16 million. Emergent Biosolutions had a negative net margin of 2.04% and a positive return on equity of 6.68%. Emergent Biosolutions’s quarterly revenue was up 79.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.55 EPS. On average, analysts forecast that Emergent Biosolutions will post 3.04 earnings per share for the current fiscal year.
In other news, Director Kathryn C. Zoon sold 1,509 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $56.12, for a total value of $84,685.08. Following the completion of the sale, the director now owns 21,494 shares of the company’s stock, valued at approximately $1,206,243.28. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 14.10% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. Earnest Partners LLC raised its holdings in shares of Emergent Biosolutions by 860.6% in the 2nd quarter. Earnest Partners LLC now owns 1,692,171 shares of the biopharmaceutical company’s stock valued at $81,749,000 after purchasing an additional 1,516,013 shares in the last quarter. Jennison Associates LLC raised its position in shares of Emergent Biosolutions by 197.0% in the second quarter. Jennison Associates LLC now owns 562,121 shares of the biopharmaceutical company’s stock valued at $27,156,000 after buying an additional 372,857 shares during the last quarter. Tygh Capital Management Inc. raised its position in shares of Emergent Biosolutions by 211.1% in the third quarter. Tygh Capital Management Inc. now owns 298,488 shares of the biopharmaceutical company’s stock valued at $15,605,000 after buying an additional 202,527 shares during the last quarter. Wells Fargo & Company MN increased its position in Emergent Biosolutions by 119.5% during the second quarter. Wells Fargo & Company MN now owns 344,191 shares of the biopharmaceutical company’s stock worth $16,628,000 after purchasing an additional 187,359 shares during the last quarter. Finally, Morgan Stanley increased its position in Emergent Biosolutions by 218.1% during the second quarter. Morgan Stanley now owns 270,769 shares of the biopharmaceutical company’s stock worth $13,081,000 after purchasing an additional 185,660 shares during the last quarter. 87.75% of the stock is owned by institutional investors and hedge funds.
Emergent Biosolutions Company Profile
Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.
See Also: How to interpret a stock’s beta number
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.